Skip to content

What's New — Hip — August 2026

13 new articles published this month.

Themes: THA in High-DDH & Osteotomy · Periprosthetic Fracture Revision · Femoral Head Preservation · Obesity & Metabolic Optimization · Outcomes Prediction & Recovery

Digest generated 2026-09-04 19:52:37+00:00.

Highlights

THA in High-DDH & Osteotomy

Two large series refine femoral shortening osteotomy technique for high-grade developmental dysplasia. Li et al. identified radiographic risk factors for delayed union or nonunion after subtrochanteric transverse osteotomy in Crowe IV hips [7], while Macheras et al. reported 25-year outcomes across five osteotomy techniques in Hartofilakidis type C dysplasia, with all acetabular components placed in the true acetabulum [11]. Together they inform osteotomy level selection and union expectations when substantial limb lengthening is required.

Periprosthetic Fracture Revision

Modular fluted tapered stems remain the workhorse for Vancouver B2/B3 periprosthetic femoral fractures. Park et al. found curved distal stems protective against intraoperative fracture extension and postoperative subsidence compared with straight stems over long-term follow-up [8]. Stem choice and canal fit are key technical considerations in this revision population.

Femoral Head Preservation

Joint-preserving strategies show durable results. Filan et al. demonstrated excellent PROMs and low reoperation or conversion-to-arthroplasty rates at minimum 5 years after arthroscopic pincer FAI correction in acetabular retroversion [1]. Restrepo et al. reported minimum 10-year survivorship free of collapse and conversion to THA for corticosteroid-induced pre-collapse osteonecrosis treated with hip decompression augmented with BMAC and PRP [4].

Obesity & Metabolic Optimization

Metabolic factors increasingly shape arthroplasty candidacy and outcomes. Bauer et al. compared direct anterior versus posterolateral approaches in morbidly obese THA patients with 90-day complication analysis [12]. Avram et al. reviewed GLP-1 receptor agonist implications for obesity, inflammation, infection risk, and surgical candidacy across hip, knee, and shoulder arthroplasty [6]. Ganz et al. addressed perioperative considerations for the rising number of arthroplasty patients on testosterone replacement therapy [3].

Outcomes Prediction & Recovery

Prediction and measurement of recovery after THA advanced on several fronts. Huffman et al. showed preoperative hip abductor strength predicts 12-month HOOS-JR and VR-12 outcomes [5]. Chen et al. integrated sensor-based gait analysis, isokinetic strength, and PROMs to map one-year recovery trajectories in elderly patients [10]. Abul et al. evaluated AI diagnostic accuracy on day-one radiographs for predicting dislocation and aseptic loosening [9]. Kwaczala et al. found robotic assistance not economical versus conventional or navigated THA when patient profiles are controlled [13]. Chen et al. critiqued CMS functional status measures, advocating meaningful outcome assessment over process compliance [2].

Articles by Theme

THA in High-DDH & Osteotomy (2)

7. Li H, Li M, Zhang B, et al. Risk Factor Analysis of Delayed Union or Nonunion After Total Hip Arthroplasty Combined with Subtrochanteric Transverse Osteotomy in Patients Who have Crowe Type IV Developmental Dysplasia of the Hip. The Journal of Arthroplasty 2026. doi:10.1016/j.arth.2026.07.044

This retrospective study of 107 patients (130 hips) with Crowe IV developmental dysplasia of the hip analyzed radiographic risk factors for delayed union or nonunion after total hip arthroplasty combined with subtrochanteric transverse osteotomy. Multiple osteotomy and canal fill parameters were compared between patients with uneventful union and those with delayed or failed union. Identifying these risk factors can guide surgical technique refinement to reduce this major complication and improve rehabilitation outcomes.

11. Macheras G, Argyrou C, Tzefronis D, et al. Femoral Shortening Osteotomy Techniques in Total Hip Arthroplasty for Hartofilakidis Type C Developmental Hip Dysplasia: A 25-Year Single-Surgeon Series. The Journal of Arthroplasty 2026. doi:10.1016/j.arth.2026.08.003

A single-surgeon 25-year retrospective series of 117 THAs with femoral shortening osteotomy in 89 patients with Hartofilakidis type C developmental dysplasia evaluated five osteotomy techniques, all with acetabular components placed in the true acetabulum. Subtrochanteric osteotomy was the most frequently used technique, with outcomes assessed for union, leg-length restoration, rotational alignment, and neurologic complications. The findings support tailoring the shortening osteotomy level and technique to individual anatomy when reconstructing the true acetabulum in high-grade DDH.

Periprosthetic Fracture Revision (1)

8. Park C, Chang Jang M, Jeong S, et al. Modular Fluted Tapered Stems in Periprosthetic Femoral Fractures: Curved Stems are Protective Against Intraoperative Fracture and Postoperative Subsidence. The Journal of Arthroplasty 2026. doi:10.1016/j.arth.2026.07.043

This single-institution study reviewed 89 revision hip arthroplasties using modular fluted tapered stems for Vancouver B2/B3 periprosthetic femoral fractures with minimum 2-year follow-up, comparing straight versus curved distal stems. Curved stems were protective against additional intraoperative fracture and postoperative stem subsidence on multivariate analysis. Surgeons managing periprosthetic femoral fractures may consider curved modular fluted tapered stems to reduce intraoperative fracture risk and improve implant stability.

Femoral Head Preservation (2)

1. Filan D, Mullins K, Carton P. Arthroscopic Correction of Pincer-Type FAI in the Presence of Acetabular Retroversion Results in Excellent Patient-Reported Outcomes With Low Risk of Reoperation or Conversion to Arthroplasty at Minimum 5 Years. The American Journal of Sports Medicine 2026. doi:10.1177/03635465261464485

This cohort study evaluated 5-year outcomes after arthroscopic correction of pincer-type femoroacetabular impingement in hips with acetabular retroversion using a prospective hip preservation registry. Patients achieved excellent patient-reported outcome measures with low rates of reoperation and conversion to arthroplasty at minimum 5-year follow-up. The findings support hip arthroscopy as a durable treatment option for symptomatic pincer-type FAI associated with acetabular retroversion.

4. Restrepo DJ, Smith JH, Guarin Perez SF, et al. Hip Decompression Augmented With Bone Marrow Aspirate Concentrate and Platelet-Rich Plasma for Corticosteroid-Induced Osteonecrosis of the Femoral Head: A Minimum 10-Year Follow-Up. The Journal of Arthroplasty 2026. doi:10.1016/j.arth.2026.07.055

This prospective cohort study reported minimum 10-year follow-up of 21 patients (34 hips) with pre-collapse corticosteroid-induced osteonecrosis of the femoral head treated with hip decompression augmented with bone marrow aspirate concentrate and platelet-rich plasma. Survivorship free from conversion to total hip arthroplasty was 62% at a mean of 11 years, with failures driven by femoral head collapse and persistent pain. The results suggest biologic augmentation provides intermediate-term benefit in only a subset of patients, informing patient selection and counseling for joint-preserving surgery.

Obesity & Metabolic Optimization (3)

3. Ganz MP, Mont MA, Scuderi GR. Androgen Awareness: Navigating Testosterone Replacement Therapy in Total Joint Arthroplasty. The Journal of Arthroplasty 2026. doi:10.1016/j.arth.2026.06.013

This review addresses the rising prevalence of testosterone replacement therapy (TRT) among patients presenting for total joint arthroplasty, driven by longevity medicine, expanded indications, and gender-affirming care. It outlines the clinical considerations orthopaedic surgeons must navigate regarding exogenous androgen use in the perioperative setting. Clinicians should increasingly recognize and manage TRT-related issues as younger, medically optimised patients undergo elective arthroplasty.

6. Avram GM, Indelli PF, Violante B, et al. GLP‐1 receptor agonists in hip, knee and shoulder arthroplasty: Implications for obesity, osteoarthritis, metabolic optimisation and complications. Knee Surgery, Sports Traumatology, Arthroscopy 2026. doi:10.1002/ksa.70557

This editorial reviews the implications of GLP-1 receptor agonist use for hip, knee, and shoulder arthroplasty, covering obesity management, metabolic optimization, and perioperative outcomes. Observational data suggest preoperative GLP-1 use may reduce periprosthetic joint infection, readmission, and other adverse outcomes, though evidence is limited by confounding and inconsistent reporting of drug class, dose, and duration. The authors emphasize the need for standardised reporting and higher-quality studies before firm clinical recommendations can be made.

12. Bauer JA, Birbara B, Grosso MJ. Comparison of 90-Day Complications Between Direct Anterior and Postero-Lateral Total Hip Arthroplasty in Morbidly Obese Patients. The Journal of Arthroplasty 2026. doi:10.1016/j.arth.2026.08.006

This retrospective review of 5,933 primary THAs compared 90-day outcomes between direct anterior (238) and posterolateral (127) approaches in 365 morbidly obese patients, using multivariable and penalized logistic regression with propensity-score sensitivity analyses. Direct anterior approach was associated with shorter operative times (71 vs 92 minutes) and reduced risk of periprosthetic fracture on adjusted analysis. These results suggest the direct anterior approach may offer perioperative advantages in morbidly obese patients, though approach selection should weigh these benefits against other complication risks.

Outcomes Prediction & Recovery (5)

2. Chen AF, Della Valle CJ, Bostrom MP, et al. Reconsidering Centers for Medicare & Medicaid Services Functional Status Measures for Total Hip and Knee Arthroplasty: From Process Compliance to Meaningful Outcome Assessment. The Journal of Arthroplasty 2026. doi:10.1016/j.arth.2026.05.075

This commentary critiques the CMS functional status measures for total hip and knee arthroplasty, arguing they function as process compliance metrics rather than meaningful assessments of patient outcomes. The authors contend that current approaches fall short of the promise shown by validated PROMs and large-scale registry initiatives in Scandinavia and the UK. They call for redesigning these measures to capture genuine patient-centered functional outcomes rather than documentation compliance.

5. Huffman A, Burbelo A, Clark T, et al. Preoperative Hip Abductor Muscle Strength Predicts Patient-Reported Functional Outcomes Following Total Hip Arthroplasty. The Journal of Arthroplasty 2026. doi:10.1016/j.arth.2026.07.049

This prospective study of 163 primary total hip arthroplasty patients used adjusted linear mixed-effects models to test whether preoperative hip abductor muscle strength predicts 12-month patient-reported outcomes. Greater preoperative ipsilateral hip abductor strength was associated with better 12-month HOOS-JR and VR-12 scores. Preoperative abductor strengthening may represent a modifiable target for prehabilitation to improve postoperative functional recovery.

9. Abul MS, Sevim ÖF, Kılıç NC, et al. Diagnostic Accuracy of Artificial Intelligence Systems in Early Prediction of Dislocation and Aseptic Loosening After Total Hip Arthroplasty. The Journal of Arthroplasty 2026. doi:10.1016/j.arth.2026.07.013

Researchers retrospectively applied multiple artificial intelligence systems to first-day postoperative pelvic radiographs from 1,045 primary total hip arthroplasty patients to predict dislocation and aseptic loosening over a mean 11.6-year follow-up. The best-performing system achieved AUCs of 0.91 (dislocation) and 0.90 (aseptic loosening) with reproducible outputs, outperforming the other systems (AUCs 0.77-0.84). AI analysis of early postoperative radiographs may enable risk stratification for late THA complications, though performance varies substantially across systems.

10. Chen W, Wang C, Lee S, et al. Sensor-Based Gait Recovery Analysis After Total Hip and Knee Arthroplasty: A One-Year Follow-Up Study Integrating Muscle Strength and Patient-Reported Outcomes. The Journal of Arthroplasty 2026. doi:10.1016/j.arth.2026.05.038

In this prospective cohort of 84 elderly patients (≥70 years) undergoing THA or TKA, foot-mounted inertial sensors tracked spatiotemporal gait parameters alongside isokinetic muscle strength testing and PROMs (HOOS-JR/KOOS-JR) at five timepoints over one year. TKA patients showed significant and persistent gait asymmetry up to three months postoperatively, whereas recovery trajectories differed between the two procedures. Objective sensor-based gait analysis combined with strength and PROM data can identify prolonged recovery phases and guide targeted rehabilitation after lower-limb joint arthroplasty.

13. Kwaczala AT, Strecker SE, Solomito MJ, et al. Implementation of Robotic-Assisted Procedure for Total Hip Arthroplasty Is Not Economical in a High-Volume Orthopaedic Facility. JAAOS: Global Research and Reviews 2026. doi:10.5435/jaaosglobal-d-25-00431

In this retrospective study of 3,799 THA patients matched on age, BMI, Charlson Comorbidity Index, and preoperative HOOS-JR, outcomes were compared across conventional (68%), robotic-assisted (10%), and computer-navigated techniques with follow-up to one year. Despite reported clinical benefits of advanced technology, the authors concluded that robotic-assisted THA was not economical in a high-volume facility, with no clear patient-reported outcome advantage over conventional or navigated approaches. Routine robotic assistance may not be cost-justified for primary THA when patient profiles are well controlled.

Creative Commons BY-NC 4.0

CC Creative Commons licence
BY Attribution — you must credit the source
NC NonCommercial — not for commercial use

Attribution-NonCommercial 4.0 International

Creative Commons Corporation ("Creative Commons") is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an "as-is" basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC- licensed material, or material used under an exception or limitation to copyright. More considerations for licensors: wiki.creativecommons.org/Considerations_for_licensors

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor's permission is not necessary for any reason--for example, because of any applicable exception or limitation to copyright--then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public: wiki.creativecommons.org/Considerations_for_licensees

Creative Commons Attribution-NonCommercial 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NonCommercial 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 -- Definitions.

a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

d. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

f. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.

i. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.

j. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

k. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

l. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 -- Scope.

a. License grant.

1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and

b. produce, reproduce, and Share Adapted Material for NonCommercial purposes only.

2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

3. Term. The term of this Public License is specified in Section 6(a).

4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a) (4) never produces Adapted Material.

5. Downstream recipients.

a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

2. Patent and trademark rights are not licensed under this Public License.

3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.

Section 3 -- License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

a. Attribution.

1. If You Share the Licensed Material (including in modified form), You must:

a. retain the following if it is supplied by the Licensor with the Licensed Material:

i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

ii. a copyright notice;

iii. a notice that refers to this Public License;

iv. a notice that refers to the disclaimer of warranties;

v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 -- Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only;

b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 -- Disclaimer of Warranties and Limitation of Liability.

a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.

b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.

c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 -- Term and Termination.

a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 -- Other Terms and Conditions.

a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 -- Interpretation.

a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.

Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark "Creative Commons" or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.